Apoptosis-related gene expression in tumor tissue samples obtained from patients diagnosed with glioblastoma multiforme

Blahovcova,Eva; Richterova,Romana; Kolarovszki,Branislav; Dobrota,Dusan; Racay,Peter; Hatok,Jozef

doi:10.3892/ijmm.2015.2369

Apoptosis-related gene expression in tumor tissue samples obtained from patients diagnosed with glioblastoma multiforme

Authors:
- Eva Blahovcova
- Romana Richterova
- Branislav Kolarovszki
- Dusan Dobrota
- Peter Racay
- Jozef Hatok
View Affiliations

Affiliations: Department of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, SK-03601 Martin, Slovakia, Clinic of Neurosurgery, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava and University Hospital in Martin, SK-03601 Martin, Slovakia
Published online on: October 12, 2015 https://doi.org/10.3892/ijmm.2015.2369
Pages: 1677-1684

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumors of the brain are very diverse in their biological behavior and are therefore considered a major issue in modern medicine. The heterogeneity of gliomas, their clinical presentation and their responses to treatment makes this type of tumor a challenging area of research. Glioblastoma multiforme (GBM) is the most common, and biologically the most aggressive, primary brain tumor in adults. The standard treatment for patients with newly diagnosed GBM consists of surgical resection, radiotherapy and chemotherapy. However, resistance to chemotherapy is a major obstacle to successful treatment. The aim of this study was to examine the changes occurring in the expression levels of apoptosis‑associated genes in tumor tissue biopsy samples from 7 patients diagnosed with GBM and compare our results with a human astrocyte cell line (used as a reference) cultured under basic conditions. For molecular analysis, we used a commercial pre-designed microfluidic array to quantify the expression of 93 apoptosis‑associated human genes. Significant changes in the expression levels of genes were observed in the tumor tissue samples obtained from patients with GBM. We determined significant changes in gene expression (n=32) in all apoptotic signaling pathways (BCl-2, TNF, Caspases, NF‑κB, IAP and CARD), while the most pronounced deregulation (>5‑fold) were observed in 46.9% events. The results of this study underline the importance of apoptosis in heterogenous tumor tissue. The identification of the apoptotic gene panel in tissue biopsies from patients with GBM may help improve the effectiveness of treatments for GBM in clinical practice and may broaden our understanding of brain tumor cell metabolism. Recognizing the changes in the expression of pro-apoptotic and anti‑apoptotic genes may aid in the development of novel treatment strategies founded on a molecular basis.

View Figures

View References

1	Richterová R, Jurečeková J, Evinová A, Kolarovszki B, Benčo M, De Riggo J, Sutovský J, Mahmood S, Račay P and Dobrota D: Most frequent molecular and immunohistochemical markers present in selected types of brain tumors. Gen Physiol Biophys. 33:259–279. 2014. View Article : Google Scholar : PubMed/NCBI
2	Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K and Delattre JY: Primary brain tumours in adults. Lancet. 379:1984–1996. 2012. View Article : Google Scholar : PubMed/NCBI
3	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
4	Persano L, Rampazzo E, Basso G and Viola G: Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting. Biochem Pharmacol. 85:612–622. 2013. View Article : Google Scholar
5	Persson AI, Petritsch C, Swartling FJ, Itsara M, Sim FJ, Auvergne R, Goldenberg DD, Vandenberg SR, Nguyen KN, Yakovenko S, et al: Non-stem cell origin for oligodendroglioma. Cancer Cell. 18:669–682. 2010. View Article : Google Scholar : PubMed/NCBI
6	Kreso A and Dick JE: Evolution of the cancer stem cell model. Cell Stem Cell. 14:275–291. 2014. View Article : Google Scholar : PubMed/NCBI
7	Pointer KB, Clark PA, Zorniak M and Arlfaei BM: Glioblastoma cancer stem cells: Biomarker and therapeutic advances. Neurochem Int. 71:1–7. 2014. View Article : Google Scholar : PubMed/NCBI
8	Schonberg DL, Lubelski D, Miller TE and Rich JN: Brain tumor stem cells: Molecular characteristics and their impact on therapy. Mol Aspects Med. 39:82–101. 2014. View Article : Google Scholar
9	Jovčevska I, Kočevar N and Komel R: Glioma and glioblastoma how much do we (not) know? Mol Clin Oncol. 1:935–941. 2013.
10	Ohgaki H and Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 170:1445–1453. 2007. View Article : Google Scholar : PubMed/NCBI
11	Tirapelli LF, Bolini PH, Tirapelli DP, Peria FM, Becker AN, Saggioro FP and Carlotti CG Jr: Caspase-3 and Bcl-2 expression in glioblastoma: an immunohistochemical study. Arq Neuropsiquiatr. 68:603–607. 2010. View Article : Google Scholar : PubMed/NCBI
12	Ohgaki H and Kleihues P: Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 100:2235–2241. 2009. View Article : Google Scholar : PubMed/NCBI
13	Iacob G and Dinca EB: Current data and strategy in glioblastoma multiforme. J Med Life. 2:386–393. 2009.
14	Ahmed R, Oborski MJ, Hwang M, Lieberman FS and Mountz JM: Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Manag Res. 6:149–170. 2014.PubMed/NCBI
15	Bralten LBC and French PJ: Genetic alterations in glioma. Cancers. 3:1129–1140. 2011. View Article : Google Scholar : PubMed/NCBI
16	Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC and Cavenee WK: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 61:215–225. 2002.PubMed/NCBI
17	Barazzuol L, Jena R, Burnet NG, Jeynes JC, Merchant MJ, Kirkby KJ and Kirkby NF: In vitro evaluation of combined temozolomide and radiotherapy using X rays and high-linear energy transfer radiation for glioblastoma. Radiat Res. 177:651–662. 2012. View Article : Google Scholar : PubMed/NCBI
18	Fruehauf JP, Brem H, Brem S, Sloan A, Barger G, Huang W and Parker R: In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res. 12:4523–4532. 2006. View Article : Google Scholar : PubMed/NCBI
19	Westhoff MA, Brühl O, Nonnenmacher L, Karpel-Massler G and Debatin KM: Killing me softly - future challenges in apoptosis research. Int J Mol Sci. 15:3746–3767. 2014. View Article : Google Scholar : PubMed/NCBI
20	Redmond KM, Wilson TR, Johnston PG and Longley DB: Resistance mechanisms to cancer chemotherapy. Front Biosci. 13:5138–5154. 2008. View Article : Google Scholar : PubMed/NCBI
21	Riffkin CD, Gray AZ, Hawkins CJ, Chow CW and Ashley DM: Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction. Neuro Oncol. 3:229–240. 2001.PubMed/NCBI
22	Krajewski S, Krajewska M, Ehrmann J, Sikorska M, Lach B, Chatten J and Reed JC: Immunohistochemical analysis of bcl-2, Bcl-X, Mcl-1, and Bax in tmors of central and peripheral nervous system origin. Am J Pathol. 150:805–814. 1997.PubMed/NCBI
23	Kogel D, Fulda S and Mittelbronn M: Therapeutic exploitation of apoptosis and autophagy for glioblastoma. Anticancer Agents Med Chem. 10:438–449. 2010. View Article : Google Scholar : PubMed/NCBI
24	Portt L, Norman G, Clapp C, Greenwood M and Greenwood MT: Anti-apoptosis and cell survival: a review. Biochim Biophys Acta. 1813:238–259. 2011. View Article : Google Scholar
25	Fulda S and Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 25:4798–4811. 2006. View Article : Google Scholar : PubMed/NCBI
26	Putcha GV, Harris CA, Moulder KL, Easton RM, Thompson CB and Johnson EM Jr: Intrinsic and extrinsic pathway signaling during neuronal apoptosis: lessons from the analysis of mutant mice. J Cell Biol. 157:441–453. 2002. View Article : Google Scholar : PubMed/NCBI
27	Thomas S, Quinn BA, Das SK, Dash R, Emdad L, Dasgupta S, Wang XY, Dent P, Reed JC, Pellecchia M, Sarkar D and Fisher PB: Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets. 17:61–75. 2013. View Article : Google Scholar
28	Tchoghadjian A, Jennewein C, Eckhardt I, Momma S, Branger DF and Fulda S: Smac mimetic promotes glioblastoma cancer stem-like cell differntiation by activating NF-κB. Cell Death Differ. 21:735–747. 2014. View Article : Google Scholar
29	Sayers TJ: Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother. 60:1173–1180. 2011. View Article : Google Scholar : PubMed/NCBI
30	Wong RS: Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011. View Article : Google Scholar : PubMed/NCBI
31	Hervouet E, Cheray M, Vallette FM and Cartron PF: DNA methylation and apoptosis resistance in cancer cells. Cells. 2:545–573. 2013. View Article : Google Scholar : PubMed/NCBI
32	Kelly G and Strasser A: The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ. 18:1414–1424. 2011. View Article : Google Scholar : PubMed/NCBI
33	Llambi F and Green DR: Apoptosis and oncogenesis: give and take in the BCL-2 family. Curr Opin Genet Dev. 21:12–20. 2011. View Article : Google Scholar : PubMed/NCBI
34	Kim H, Tu HC, Ren D, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJ and Cheng EH: Stepwise activation of Bax and Bak by tBid, Bim, and Puma initiates mitochondrial apoptosis. Mol Cell. 36:487–499. 2009. View Article : Google Scholar : PubMed/NCBI
35	Bender A, Opel D, Naumann I, Kappeler R, Friedman L, von Schweinitz D, Debatin KM and Fulda S: PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis. Oncogene. 30:494–503. 2011. View Article : Google Scholar
36	Ghobrial IM, Witzig TE and Adjei AA: Targeting apoptosis pathways in cancer therapy. Cancer J Clin. 55:178–194. 2005. View Article : Google Scholar
37	Zubor P, Hatok J, Moricova P, Kapustova I, Kajo K, Mendelova A, Sivonova MK and Danko J: Gene expression profiling of histologically normal breast tissue in females with human epidermal growth factor receptor 2-positive breast cancer. Mol Med Rep. 11:1421–1427. 2015.
38	Zubor P, Hatok J, Galo S, Dokus K, Klobusiakova D, Danko J and Racay P: Anti-apoptotic and pro-apoptotic gene expression evaluated from eutopic endometrium in the proliferative phase of the menstrual cycle among women with endometriosis and healthy controls. Eur J Obstet Gynecol Reprod Biol. 145:172–176. 2009. View Article : Google Scholar : PubMed/NCBI
39	Vitucci M, Hayes DN and Miller CR: Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. Br J Cancer. 104:545–553. 2011. View Article : Google Scholar :
40	Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
41	Shiozaki EN and Shi Y: Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends Biochem Sci. 29:486–494. 2004. View Article : Google Scholar : PubMed/NCBI
42	Shi Y: Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell. 9:459–470. 2002. View Article : Google Scholar : PubMed/NCBI
43	Verhagen AM, Coulson EJ and Vaux DL: Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol. 2:REVIEWS3009. 2001. View Article : Google Scholar : PubMed/NCBI
44	Maier JK, Lahoua Z, Gendron NH, Fetni R, Johnston A, Davoodi J, Rasper D, Roy S, Slack RS, Nicholson DW and MacKenzie AE: The neuronal apoptosis inhibitory protein is a direct inhibitor of caspases 3 and 7. J Neurosci. 22:2035–2043. 2002.PubMed/NCBI
45	Holcik M, Thompson CS, Yaraghi Z, Lefebvre CA, MacKenzie AE and Korneluk RG: The hippocampal neurons of neuronal apoptosis inhibitory protein 1 (NAIP1)-deleted mice display increased vulnerability to kainic acid-induced injury. Proc Natl Acad Sci USA. 97:2286–2290. 2000. View Article : Google Scholar : PubMed/NCBI
46	Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B and Bao JK: Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 45:487–498. 2012. View Article : Google Scholar : PubMed/NCBI
47	Ghavami S, Hashemi M, Ande SR, Yeganeh B, Xiao W, Eshraghi M, Bus CJ, Kadkhoda K, Wiechec E, Halayko AJ and Los M: Apoptosis and cancer: mutations within caspase genes. J Med Genet. 46:497–510. 2009. View Article : Google Scholar : PubMed/NCBI
48	Kurokawa M and Kornbluth S: Caspases and kinases in a death grip. Cell. 138:838–854. 2009. View Article : Google Scholar : PubMed/NCBI
49	Tanase C, Albulescu R, Codrici E, Calenic B, Popescu ID, Mihai S, Necula L, Cruceru ML and Hinescu ME: Decreased expression of APAF-1 and increased expression of cathepsin B in invasive pituitary adenoma. Onco Targets Ther. 8:81–90. 2014. View Article : Google Scholar
50	Yuan S and Akey CW: Apoptosome structure, assembly and procaspase activation. Structure. 21:501–515. 2013. View Article : Google Scholar : PubMed/NCBI
51	Mouhamad S, Galluzzi L, Zermati Y, Castedo M and Kroemer G: Apaf-1 deficiency causes chromosomal instability. Cell Cycle. 24:3103–3107. 2007. View Article : Google Scholar
52	Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 91:479–489. 1997. View Article : Google Scholar : PubMed/NCBI
53	Karsy M, Neil JA, Guan J, Mark MA, Colman H and Jensen RL: A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg Focus. 38:E42015. View Article : Google Scholar : PubMed/NCBI
54	Wei B, Wang I, Du Ch, Hu G, Wang L, Jin Y and Kong D: Identification of differentially expressed genes regulated by transcription factors in glioblastomas by bioinformatics analysis. Mol Med Rep. 11:2548–2554. 2015.
55	Stancheva G, Goranova T, Laleva M, Kamenova M, Mitkova A, Velinov N, Poptodorov G, Mitev V, Kaneva R and Gabrovsky N: IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients. Biomed Res Int. 2014:6547272014. View Article : Google Scholar : PubMed/NCBI
56	England B, Huang T and Karsy M: Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumor Biol. 34:2063–2074. 2013. View Article : Google Scholar
57	Li J, Di Ch, Mattox AK, Wu L and Adamson DC: The future role of personalized medicine in the treatment of glioblastoma multiforme. Pharmacogen Personal Med. 3:111–127. 2010.
58	Vogler M: Targeting BCL2 proteins for the treatment of solid tumours. Advances in Medicine. 2014:ID 943648. 2014. View Article : Google Scholar
59	Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
60	Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Böck BC, Macher-Goeppinger S, Radlwimmer B, Wiestler OD, Herold-Mende C and Roth W: Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene. 27:6646–6656. 2008. View Article : Google Scholar : PubMed/NCBI
61	Reed JC, Meister L, Tanaka S, Cuddy M, Yum S, Geyer C and Pleasure D: Differential expression of bcl2 protooncogene in neuroblastoma and others human tumor cell lines of neural origin. Cancer Res. 51:6529–6538. 1991.PubMed/NCBI
62	Mercer EA, Korhonen L, Skoglösa Y, Olsson PA, Kukkonen JP and Lindholm D: NAIP interacts with hippocalcin and protects neurons against calcium-induced cell death through caspase-3-dependent and -independent pathways. EMBO J. 19:3597–3607. 2000. View Article : Google Scholar : PubMed/NCBI
63	Wen X, Lin ZQ, Liu B and Wei YQ: Caspase-mediated programmed cell death pathways as potential therapeutic targets in cancer. Cell Prolif. 45:217–224. 2012. View Article : Google Scholar : PubMed/NCBI
64	Ashley DM, Riffkin CD, Muscat AM, Knight MJ, Kaye AH, Novak U and Hawkins CJ: Caspase 8 is absent or low in many ex vivo gliomas. Cancer. 104:1487–1496. 2005. View Article : Google Scholar : PubMed/NCBI
65	Yoshino A, Ogino A, Yachi K, Ohta T, Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Naruse N, Sano E and Tsumoto K: Gene expression profiling predicts response to temozolomide in malignant gliomas. Int J Oncol. 36:1367–1377. 2010. View Article : Google Scholar : PubMed/NCBI
66	Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, Vogel H, Recht LD, Scheck AC and Sikic BI: Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol. 24:274–287. 2006. View Article : Google Scholar
67	Saggioro FP, Neder L, Stávale JN, Paixao-Becker AN, Malheiros SM, Soares FA, Pittella JE, Matias CC, Colli BO, Carlotti CG Jr, et al: Fas, FasL, and cleaved caspases 8 and 3 in glioblastomas: a tissue microarray-based study. Pathol Res Pract. 210:267–273. 2014. View Article : Google Scholar : PubMed/NCBI
68	Siegelin MD, Gaiser T and Siegelin Y: The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP. Neurochem Int. 55:423–30. 2009. View Article : Google Scholar : PubMed/NCBI